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Managing self poisoning
Gastric lavage is perhaps more important
in developing countries
Editor—In their clinical review of recent
advances in the management of self poison-
ing, Jones and Volans briefly discuss gastric
lavage and state: “many clinical toxicologists
rarely use this method now.”1 The impres-
sion given could support the abandonment
of gastric lavage. This could be particularly
deleterious in developing countries.
In developing countries, poisons con-
sumed are commonly toxins such as
organophosphorus compounds and alu-
minium phosphide, and thus mortality is
high. The organophosphorus compounds
are usually consumed in liquid form. In such
cases of poisoning, prevention of absorption
of even a small amount may make a consid-
erable difference. Furthermore, antidotes to
poisons and intensive care may not be avail-
able. Any intervention, such as gastric
lavage, which can be carried out easily
cannot be neglected. The value of gastric
lavage depends on the amount, toxicity, and
effect of the poison and the time since con-
sumption. Its role in certain cases should
have been highlighted.
Madhur Dev Bhattarai postgraduate teacher
Department of Medicine, Bir Hospital, Kathmandu,
Nepal
mdb@mos.com.np
1 Jones AL, Volans G. Management of self poisoning. BMJ
1999;319:1414-7. (27 November.)
Common sense makes no sense
Editor—Although Jones and Volans’s arti-
cle updating doctors on the management of
poisoning is welcome and informative, I was
a little bemused by the contradictions in it.1
We are told that gastric lavage should
not be used unless two criteria are met: it
should be used within an hour of ingestion
of the poison, and the amount of toxin
should be substantial. Though these criteria
are repeated often in the literature there is
no evidence to support either of them. The
literature indicates only that there is no
difference in outcome when gastric lavage is
used. But Jones and Volans—like the authors
of the papers quoted—give way to that devil,
common sense.
It makes sense to try to remove a toxin
before it is absorbed; therefore, when the
poisoning may be serious, scrap the
evidence, go for common sense, and do a
gastric lavage. How, in real life, we are accu-
rately to determine the time of ingestion and
amount of toxin ingested in a group of
patients who are notoriously unreliable is a
moot point.
We see the same reversion to common
sense in Jones and Volans’ update on carbon
monoxide poisoning. The most rapid way to
displace and eliminate carbon monoxide is
to use hyperbaric oxygen—there is no doubt
about this fact in the literature. But if we are
informed that the usefulness of hyperbaric
oxygen is far from proved then surely we
must consider it seriously in all patients on
the grounds of common sense, or we must
not use it at all on the grounds of evidence.
Incidentally, there is no evidence showing
selective benefit in those patients who have
been obtunded, and to preach such a quali-
fication is unjustified.
I welcome evidence based medicine
wholeheartedly but can’t help smiling when
I encounter authorities making clearcut rec-
ommendations . . . up to a point—the point
after which they get cold feet.
Dilip DaCruz visiting consultant in emergency
medicine
Accident and Emergency Department, Khoula
Hospital, Muscat, Oman
missile@gto.net.om
1 Jones AL, Volans G. Management of self poisoning. BMJ
1999;319:1414-7. (27 November.)
Guidelines for accident and emergency
departments are needed
Editor—In their review on the manage-
ment of self poisoning Jones and Volans
suggest that decontaminating the gut by
gastric lavage or administration of activated
charcoal be carried out within one hour of
ingestion of the toxin.1 In practice, however,
it is rare for such patients to present at an
accident and emergency department and to
be assessed within one hour of ingestion.
There are many reasons for this, including
patients’ delay in seeking help, transporta-
tion time to hospital, and triage category.
The average time from receipt of an
emergency call to arrival at hospital is 38
minutes for all patients in the West Midlands
area (S Edwards, West Midlands Ambulance
Service, personal communication). Addi-
tionally, the standard UK triage system
assigns asymptomatic poisonings to cat-
egory 3 (to be seen within one hour of
arrival).2
As similar recommendations on time
since ingestion have already been imple-
mented in many accident and emergency
departments, gastric lavage is now seldom
performed. With this loss of training oppor-
tunity for new staff, the skills needed to per-
form the procedure safely may be lost, with
the result that it may not be performed in
the few patients in whom it remains
indicated.
Clearly, the sooner activated charcoal is
given the better. It has been given success-
fully in the prehospital setting.3 This is prob-
ably the best way, and in many cases the only
way, of administering it in the one hour time
frame that clinical toxicologists recommend.
Although the authors suggest a carboxy-
haemoglobin level of > 40% as an indica-
tion for hyperbaric oxygen therapy, another
recent review has suggested a much lower
( > 20%) level as an indication for this
therapy.4
Unlike other authors,4 5 Jones and
Volans do not include pregnancy as a
special indication for hyperbaric oxygen
therapy. The fact that two recent publica-
tions in journals from the BMJ Publishing
Group should give different recommenda-
tions for managing important aspects of
such a common problem illustrates the
divergence of opinion in this area and the
problems faced by accident and emergency
staff while making decisions.1 4
These issues need to be clarified, and
consensus guidelines relevant to the realities
Advice to authors
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in accident and emergency departments
need to be drawn up. This should ideally be
done by a joint working party of UK
toxicologists, prehospital care providers,
hyperbaric therapy clinicians, and accident
and emergency clinicians.
Mehmood Chaudhry specialist registrar in accident
and emergency medicine
Heartlands Hospital, Birmingham B9 5SS
mehmood.chaudhry@talk21.com
Rakesh Khanna specialist registrar in accident and
emergency medicine
Manor Hospital, Walsall WS2 9PS
1 Jones AL, Volans G. Management of self poisoning. BMJ
1999;319:1414-7. (27 November.)
2 Mackway-Jones K, ed. Emergency triage. London: BMJ Pub-
lishing Group, 1997.
3 Allison TB, Gough JE, Brown LH, Thomas SH. Potential
time savings by prehospital administration of activated
charcoal. Prehosp Emerg Care 1997;1:73-5.
4 Turner M, Hamilton-Farrell MR, Clark RJ. Carbon monox-
ide poisoning: an update. J Accid Emerg Med 1999;16:
96-8.
5 Ernst A, Zibark JD. Carbon monoxide poisoning. N Engl J
Med 1998;339:1603-8.
Indications for the use of whole bowel
irrigation are weak
Editor—I was surprised to see in Jones and
Volans’ review of management of self
poisoning the headline advice that when a
potentially lethal amount of a drug is not
adsorbed by activated charcoal, whole bowel
irrigation with polyethylene glycol solution
is recommended.1
One of the references cited is the Ameri-
can Academy of Clinical Toxicologists/
European Association of Poisons Centres
and Clinical Toxicologists’ position statement
on whole bowel irrigation. The position state-
ment represents a thorough review of the lit-
erature and appraisal of the data concerning
whole bowel irrigation (WBI) and states:
“There are no established indications for the
use of WBI. . . . The use of WBI for the
removal of ingested packets of illicit drugs
and in the management of patients who have
ingested substantial amounts of poisons not
adsorbed to activated charcoal is also of theo-
retical benefit.”2 This seems a weak founda-
tion for such a strong recommendation of a
procedure that is not without complications.
Michael Trimble specialist registrar
Department of Therapeutics and Pharmacology,
Queen’s University of Belfast, Belfast BT7 1NN
g.mcveigh@qub.ac.uk
1 Jones AL, Volans G. Management of self poisoning. BMJ
1999;319:1414-7. (27 November.)
2 American Academy of Clinical Toxicologists and Euro-
pean Association of Poisons Centres and Clinical
Toxicologists. Position statement: whole bowel irrigation.
J Clin Toxicol 1997;35:753-62.
Body packers need careful treatment
Editor—We support most of Jones and Vol-
ans’ recommendations concerning the man-
agement of self poisoning, which have been
reached using an evidence based approach.1
However, we think that their suggestions for
managing self poisoning among drug couri-
ers who have ingested packets of drugs
(body packers) are based on anecdotal case
histories and contradict most of the pub-
lished literature. Some of these suggestions
may be dangerous.
Methods of drug smuggling are becom-
ing increasingly sophisticated, which has led
to the development of packaging that is
more tolerant of gastrointestinal transit.
Breakdown of packages is now thought to
be relatively rare. Most authors therefore
recommend a conservative approach to
body packers who have no symptoms.2
Although there are reports of success, we
do not recommend endoscopic removal of
packages from the stomach or colon owing to
the considerable danger of perforation on
capture. With the average package of cocaine
containing 10 times the median lethal dose,
perforation is likely to be fatal.
The use of whole bowel irrigation and
laxatives is more controversial and needs
more controlled research. However,
Caruana et al report a series of 50 patients
treated with mineral oil without a single
instance of a package degrading.3 Visser et al
cast doubt on the use of mineral oil in their
report of a single case, but their patient had
shown signs of cocaine toxicity before the oil
was given, which suggests that the packet
was already starting to degrade.4
In conclusion, we recommend a con-
servative approach to treating body packers
with no symptoms. Endoscopy is contraindi-
cated and surgery should be reserved for
those with delayed transit, bowel obstruc-
tion, or signs of toxicity or passage of
damaged packages.
John Hollingsworth specialist registrar in accident
and emergency
jhollingsworth@doctors.org.uk
Robin Jones specialist registrar in accident and
emergency
University Hospital Aintree, Liverpool L9 7AL
1 Jones LJ, Volans G. Management of self poisoning. BMJ
1999;319:1414-7.
2 Glass JM, Scott HJ. “Surgical mules": the smuggling of
drugs in the gastrointestinal tract. J R Soc Med
1995;88:450-3.
3 Caruana DS, Weinbach B, Goerg D, Gardner LB. Cocaine
packet ingestion: diagnosis, management and natural
history. Ann Intern Med 1984;100:73-4.
4 Visser L, Stricker B, Hoogendoorn M, Vinks A. Do not give
paraffin to packers. Lancet 1998;352:1352.
Poisons database is still not on the NHS
net
Editor—A couple of points about Jones and
Volans’ clinical review.1 Firstly, ketamine is
not just a veterinary anaesthetic but is still
available in most operating theatres.
Secondly, it is appalling that a poisons
database is still not on the NHS net (but then
again, what is; not even the British National
Formulary). Why is so much spent on setting
up the NHS net and so little of practical
value put on it?
R Harris consultant anaesthetist
Bassetlaw Hospital Trust, Worksop S81 0JN
richard@thelimes.co.uk
1 Jones AL, Volans G. Management of self poisoning. BMJ
1999;319:1414-7. (27 November.)
Authors’ reply
Editor—We agree with Bhattarai that the
evidence on which the European and
American guidelines have been created is
largely from more developed countries and
involves overdoses of pharmaceutical
agents. However, it is probable, given the
number of studies to date, that gastric lavage
is unlikely to be of established value beyond
one hour after ingestion of a variety of
agents. When it is carried out too late, the
stomach contents may have passed into the
small bowel and gastric lavage would not be
expected to retrieve such material, except if
gastric emptying were in some way delayed.
In addition, gastric lavage can actually push
the gastric contents beyond the pylorus,
which enhances absorption.1 We must
remain vigilant to the possibility of excep-
tions, but, from our experience in Nepal with
the World Health Organization, we would
not recommend using gastric lavage with
water for aluminium or zinc phosphate poi-
soning, as contact with water liberates phos-
phine gas, which is a potent respiratory
toxin. Gastric lavage with vegetable oil is
preferred under such circumstances.
Chaudhry and Khanna make practical
points about the implications of the new
guidelines for decontamination in accident
and emergency departments. As the evi-
dence for the efficacy of gastric lavage and
activated charcoal is only for its use within
an hour, it is important that such patients
are triaged rapidly. If a considerable delay in
transit to hospital is anticipated, general
practitioners may be best placed to give acti-
vated charcoal, providing the patient is not
too drowsy or at risk of fits.2
Trimble shows that the evidence on
which some recommendations have been
made is a few case reports, and randomised
controlled clinical trials are often not
available. The guidelines are exactly that—
guidelines and not protocols. The lack of an
evidence base behind the bowel irrigation
guidelines may reflect limited experience of
the procedure, but it is a potentially
important advance in treating patients with
overdose of slow release formulations or
substances that do not bind to charcoal. We
wanted to raise awareness of whole bowel
irrigation and to indicate when we, as
clinicians, would consider using it in our
patients, though clearly more data collection
is needed to show efficacy.3 Whole bowel
irrigation may offer a new conservative
approach to treating body packers. Sadly,
there are still sudden deaths from packages
that rupture, and, as Hollingsworth and
Jones point out, the need for removal must
be judged by risk assessment. When signs of
toxicity are developing, such as cocaine tox-
icity, the need for urgent removal is pressing
and the risk assessment strongly favours
removal of the packet.
When our article was submitted to the
BMJ, TOXBASE was not available on the
internet. It is now available at www.spib.axl-
.co.uk. We contribute to updating TOX-
BASE and strongly support its use as a first
line in helping to answer poisons inquiries.
Alison L Jones consultant physician
Glyn Volans director
National Poisons Information Service, Guy’s and St
Thomas’s NHS Trust, London SE14 5ER
Letters
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1 Saetta JP, March S, Gaunt ME, Quinton DN. Gastric emp-
tying procedures in the self-poisoned patient: are we forc-
ing gastric content beyond the pylorus? J R Soc Med
1991;84:274-6.
2 Allison TB, Gough JE, Brown LH, Thomas SH. Potential
timesavings by prehospital administration of activated
charcoal. Prehosp Emerg Care 1997;1:73-5.
3 American Academy of Clinical Toxicologists and Euro-
pean Association of Poisons Centres and Clinical
Toxicologists. Position statement: whole bowel irrigation.
J Clin Toxicol 1997;35:735-62.
Health minister clarifies Care
Standards Bill
Editor—I believe that your article on
private health care was in places misleading
and factually incorrect.1 The article implies
that the Care Standards Bill will only extend
to standards of premises and equipment in
independent health care, and that the bill
will not address the core problem of the
quality of clinical care. It also wrongly
implies that the bill does not address issues
about safety and quality in cosmetic surgery.
Current regulation of the private sector
is undoubtedly inadequate and no longer
appropriate for the range of treatment pro-
vided by private hospitals. The Care
Standards Bill will address just this issue, set-
ting up a new care standards commission,
which will take on the role of regulating the
private health sector. It will oversee the
registration and inspection of private
healthcare providers and carry out annual
checks on all private facilities, including
unannounced spot checks. Where necessary
the commission will have the power to take
enforcement action, including closing a hos-
pital or a clinic down if patients are at risk.
Emphasis on quality and standards of
care will be greater under the new system.
Minimum care standards will be set that
must be met by all private healthcare
providers. In cases where things do go
wrong patients will have redress through a
proper complaints system. We will introduce
arrangements for independent investiga-
tions where patients are not satisfied with
how their complaint was handled. The regis-
tration, inspection and enforcement proc-
esses will help ensure that the organisations
running independent hospitals and clinics
will have to account for the care provided in
them.
Although it is true that the Department
of Health’s main responsibility is to ensure
that health care is managed effectively
within the NHS, that does not mean that it is
unconcerned about the safety and stand-
ards, and patients’ rights of redress, in inde-
pendent health care. This government is
determined that there is proper protection
for people who choose to use private health
care—and the Care Standards Bill will
address just this issue.
Gisela Stuart health minister
Department of Health, Richmond House, London
SWA 2NS
Paul.Z.Clark@DOH.GOV.UK
1 Beecham L. BMA seeks clarification on Care Standards
Bill. BMJ 2000;320:255. (22 January.)
Differentiating between audit
and research
Undue protection of patient
confidentiality jeopardises both research
and audit
Editor—Wilson et al have highlighted an
important double standard that distin-
guishes clinical research from audit.1 While
researchers are obliged to struggle for
ethical approval to examine patient records,2
auditors seldom have to, even though they
may be temporary, non-medical staff with-
out a long term professional commitment to
respect patient confidentiality.
The protection of confidentiality is
clearly essential in each activity, so we would
expect both to be affected equally by the
implementation of the Data Protection Act
(1998) this month. Unfortunately, it seems
that identifiable information about patients,
and access to their records, can be obtained
only with their explicit or implicit permis-
sion. The extent to which the act will require
protection of both anonymised and patient
identifiable data will affect, and even perhaps
jeopardise, epidemiological research, audit,
and therefore clinical governance. Even the
BMA’s stringent contemporary guidelines
on this issue have been deemed insuffi-
ciently protective and therefore unlawful.3
Gone will be the days of carefully
considered guidance from working parties
with strong lay membership, which have
advised that, “research involving access to
medical records, registers, or existing bio-
logical samples only, without direct patient
contact or involvement, is not considered to
require individual patient consent or inde-
pendent ethical approval provided explicit
consent to access a patient’s records is
obtained either from the official custodian
of those records or from the patient’s
clinician.”4
This kind of well intentioned protection
of patients will inevitably wreck epidemio-
logical research. Furthermore, if the same
rules are applied, we cannot see how mean-
ingful audit or clinical governance can ever
happen. For example, the interpretation of
“league tables,” or even early warning of
another Bristol, would be impossible with-
out ready access to routine patient records,
both in primary and in secondary care. The
cost to society of hampering timely medical
research and audit must surely outweigh the
risk of bona fide researchers and auditors
endangering patient confidentiality. The
uncertainty surrounding access to patient
records is causing great confusion, contra-
dictory guidelines, and fear of litigation and
is making clinical research even more
difficult than it already is.
Charles P Warlow professor of medical neurology
Rustam Al-Shahi MRC clinical training fellow
Department of Clinical Neurosciences, Western
General Hospital, Edinburgh EH4 2XU
1 Wilson A, Grimshaw G, Baker R, Thompson J. Differentiat-
ing between audit and research: postal survey of health
authorities’ views. BMJ 1999;319:1235. (6 November.)
2 Al-Shahi R, Warlow CP. Ethical approval of a multicentre
study in Scotland: a weighty problem. J R Coll Physicians
Lond 1999; 33(6): 549-52.
3 Dyer C. BMA’s patient confidentiality rules are deemed
unlawful. BMJ 1999;319:1221. (6 November.)
4 Royal College of Physicians of London. Guidelines on the
practice of ethics committees in medical research involving
human subjects. 3rd ed. London: RCP, 1996.
Clinical audit is research
Editor—In their paper Wilson et al write:
“Our experience shows that consensus is
lacking on the definition of research and
audit.”1 They are right. A dictionary defines
research as “a careful search; investigation;
systematic investigation towards increasing
the sum of knowledge.”2 The nearest it
comes to a medical definition of audit is “a
calling to account generally; a check or
examination; a periodical settlement of
accounts.”2 The best current definition is
probably Wilson et al’s: “Perhaps the most
helpful distinction (between research and
audit) is about motivation and the objectives
of the project: audit has the objective of
directly improving services against a stand-
ard; research may include the objective of
defining best practice.”1
Not everyone may agree with Wilson et
al, which is why we wrote to the BMJ in 1997.3
Our journal Anaesthesia, in its notice to
contributors, had introduced a new hurdle:
“Prospective ethics approval should be
acquired for papers based on clinical audit
data.”4 Partly as a result of our letter, we
believe, and partly from the subsequent
correspondence in the columns of BMJ,
Anaesthesia removed the hurdle. That does
not mean that the journal was entirely
convinced by the arguments. Nor does it
mean, as is clear from Wilson et al’s paper,
that health authorities and ethics committees
up and down the land are less confused now
than they were then.
Taking the dictionary definitions of
research, it is plain that clinical audit has to
be, must be, research. The remaining
question is whether an audit is ethical. Since
the Clinical Audit Committee of the BMA
seems to have taken upon itself responsibil-
ity for ethical issues in audit,5 perhaps it
should look once again at the problem and
find a definitive and non-politically correct
solution which might satisfy scientists,
writers, editors, and literary pedants.
P V Scott consultant
Department of Anaesthetics, Alexandra Hospital,
Redditch, Worcs B98 7UB
1 Wilson A, Grimshaw G, Baker R, Thompson J. Differentiat-
ing between audit and research: postal survey of health
authorities’ views. BMJ 1999;319:1235. (November 6.)
2 Kirkpatrick EM, ed. Chambers 20th Century Dictionary. Lon-
don: Chambers, 1983.
3 Scott PV, Pinnock CA. BMA’s advice about approval of
clinical audit studies is confusing. BMJ 1997;315:60.
4 Notice to contributors. Anaesthesia 1997;52:inside back
page.
5 Clinical Audit Committee. Ethical issues in audit. London:
BMA, 1995.
Authors take issue with
commentary on their paper
Editor—We commend the development of
the BMJ’s guidelines on educational inter-
ventions, which were used to assess our
paper.1 At several points in Ker’s commen-
Letters
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tary on our paper, however, she raises the
need for further information. We recognised
this need when we prepared the manuscript.
We were also aware, though, of the
constraints on space; articles in the BMJ
should not exceed 2000 words, and provid-
ing the requisite information would have
made our paper substantially longer. An
alternative would have been to give the
information on the journal’s website; this
has the disadvantage of increasing the
demands on authors but should be consid-
ered if the guidelines are to be fully applied.
We had some difficulty in following the
comments on the randomisation approach.
Firstly, it is unclear why Ker thinks the term
“controlled” should be dropped; this is the
conventional term for a trial such as this
one, entailing randomisation to two or more
groups, one of which is a control or
comparison group.
Secondly, Ker suggests that contamina-
tion threatens the status of the control
group. Presumably she is referring to the
control group experiencing the effects of the
intervention. It is certainly true that con-
tamination is a major consideration in a
study of this kind. We recognised this before
we started the study and chose the sampling
design specifically to minimise its likelihood.
We believe that contamination was minimal,
but even if this was not so it should have
reduced the chances of finding the differ-
ences that emerged. This does not represent
an absence of control.
Thirdly, Ker suggests that imbalances in
the demographic variables in the interven-
tion and control groups threaten the study’s
internal validity. Such an imbalance can
arise in randomised controlled trials, and
steps were taken in the data analysis to
adjust for baseline differences between
intervention and control groups.
Fourthly, Ker comments on the ran-
domisation process. We believe that ran-
domisation took place at the highest level
possible for this kind of community based
intervention. The suggested purposive sam-
pling method, with presumably some form
of pairwise or stratified randomisation, may
be the ideal but raises a further barrier to the
recruitment of adequate numbers of general
practitioners. By making recruitment more
difficult it would probably reduce further the
representativeness of those practitioners
who eventually participate.
Lastly, Ker’s final sentence is ambiguous.
A simple adjustment to the wording, replac-
ing “the study” with either “a study” or “this
or any other study,” would more adequately
describe her meaning.
Lena A Sanci fellow in adolescent health
sancil@cryptic.rch.unimelb.edu.au
Carolyn M M Coffey epidemiologist
George C Patton director
Glenn Bowes professorial fellow
Centre for Adolescent Health, Department of
Paediatrics, University of Melbourne, Parkville,
Melbourne 3052, Australia
1 Sanci LA, Coffey CMM, Veit FCM, Carr-Gregg M, Patton
GC, Day N, et al. Evaluation of the effectiveness of an edu-
cational intervention for general practitioners in adoles-
cent health care: randomised controlled trial [with
commentary by J Ker]. BMJ 2000;320:224-30. (22 January.)
Mortality prediction model is
preferable to APACHE
Editor—In their article on scoring systems
in intensive care, Gunning and Rowan
provide a detailed description of the
APACHE II mortality prediction model.1
This model was developed with data
collected between 1979 and 1982 and was
replaced by APACHE III in 1991.2 Unfortu-
nately, there is a substantial charge for using
APACHE III; thus many intensive care units
continue using the outdated APACHE II,
but do you really want to compare your
standard of care with that delivered by
North American units 20 years ago?
There are several other problems with
APACHE II and APACHE III. Firstly, they
use the worst value of several physiological
variables (such as blood pressure and heart
rate) in the first 24 hours in intensive care to
calculate each patient’s risk of dying. Any
score that uses data collected over 24 hours
is affected by the quality of care provided2 3—
the very thing that units are trying to assess.
Patients mismanaged in a bad unit will have
higher APACHE scores than similar patients
managed in a good unit, and the bad unit’s
high mortality will be incorrectly attributed
to its having sicker patients.
Secondly, using the worst scores in 24
hours gives a spurious impression of accu-
racy3; many deaths occur during the first 24
hours in intensive care, and during this time
the score is diagnosing death rather than pre-
dicting it (it is not difficult to detect that some-
thing is wrong with a dead patient).
Thirdly, the worst scores in 24 hours
depend on the method of data collection,
being about 25% higher with continuous
computer monitoring than with manual
recording.4
Fourthly, collecting the worst value of 15
variables over 24 hours is difficult; either a
disproportionate amount of work goes into
collecting the information (which reduces
the resources available for more creative
research) or, as often happens, it is collected
inaccurately or is not collected at all.
The mortality prediction model uses
data collected during the first hour after
admission to intensive care.2 It was devel-
oped by Stanley Lemeshow, professor of
biostatistics at the University of Massachu-
setts, who coauthored one of the standard
texts on logistic regression. The model has
been derived and tested on over 19 000
patients in Europe and North America and
is free.5 For children, the paediatric index of
mortality model uses data obtained at the
time that a child is admitted to intensive
care,3 and it too is free (http://pedsccm.
wustl.edu/clinical/pim-readme.html).
The mortality prediction model has sub-
stantial theoretical, practical, and financial
advantages over the APACHE model for use
in adults in intensive care.
Frank Shann director of intensive care
Intensive Care Unit, Royal Children’s Hospital,
Melbourne 3052, Australia
shannf@cryptic.rch.unimelb.edu.au
1 Gunning K, Rowan K. ABC of intensive care: Outcome
data and scoring systems. BMJ 1999;319:241-4. (24 July.)
2 Shann F. MPM is preferable to APACHE as an intensive
care scoring system. eBMJ 1999 (www.bmj.com/cgi/
eletters/319/7204/241#EL2) (accessed 17 February
2000).
3 Shann F, Pearson G, Slater A, Wilkinson K. Paediatric
index of mortality (PIM): a mortality prediction model for
children in intensive care. Intens Care Med 1997;23:201-7.
4 Bosman RJ, Oudemans van Straaten HM, Zandstra DF.
The use of intensive care information systems alters
outcome prediction. Intens Care Med 1998;24:953-8.
5 Lemeshow S, Le Gall JR. Modeling the severity of illness of
ICU patients: a systems update. JAMA 1994;272:1049-55.
Development and evaluation
committees’ methods for
appraising new drugs
Committee failed to meet aims in
producing report on low molecular
weight heparins
Editor—We agree with Freemantle and
Mason’s view that the methods used by
development and evaluation committees
may be inadequate for appraising new
drugs.1 The InterDEC, a collaboration
between Wessex and three other organisa-
tions, contends that none of the 100 reports
produced so far has been significantly
contradicted by later evidence.2 From per-
sonal experience we would beg to differ.
In March 1999 the Wessex Development
and Evaluation Committee published a
report on the use of low molecular weight
heparins compared with unfractionated
heparins for use in unstable angina and
non-Q wave myocardial infarction.3 The
committee claims to use a thorough system of
information search to ensure that any rele-
vant information is taken into account when
the reports are produced. Furthermore, its
aim is to provide updates of reports within a
short time when information becomes avail-
able that might alter the conclusion of the
original report. In the above case it has failed
to deliver on either of these counts.
Firstly, the report failed to identify a key
paper by Fox showing the extended benefit to
one year of treatment with enoxaparin versus
unfractionated heparins in the treatment of
unstable angina and non-Q wave myocardial
infarction.4 This omission was further com-
pounded by its failure to acknowledge several
abstracts presenting these data at inter-
national meetings. As a result of this, the
worst case scenarios were chosen for model-
ling to determine cost utility of the treatment,
resulting in a conclusion of “no proved
benefit.” If the omitted data showing a
sustained reduction of 13% at one year in
death, myocardial infarction, and recurrent
angina with enoxaparin compared with
unfractionated heparins had been included
in the assessment, the conclusion would
probably have been “proved benefit” on
grounds of both clinical and cost efficacy.
Secondly, this error was brought to the
authors’ attention in June 1999, and we have
been informed that a review is scheduled for
March this year. In our view, incorrect
conclusions and misinformation should be
dealt with expediently to ensure that
patients benefit from optimum treatment.
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Reports by development and evaluation
committees are undoubtedly a valuable con-
tribution to the evaluation of available treat-
ments and the rational provision of health-
care resources. The quality of the report
from which the conclusions are drawn must
be scientifically sound. Using the develop-
ment and evaluation committees’ own crite-
ria for scientific validity of data, is it time that
the committees’ reports are peer reviewed
before publication?
Nick Bosanquet professor of health policy
Health Policy Unit Division of Primary Care and
Population Health Sciences, Imperial College
School of Medicine, Department of Primary Health
Care and General Practice, London W2 1PG
n.bosanquet@ic.ac.uk
Keith Fox professor of cardiology
University of Edinburgh, Edinburgh EH8 9AG
1 Freemantle N. Mason J. Not playing with a full DEC: why
development and evaluation committee methods for
appraising new drugs may be inadequate. BMJ
1999;318:1480-2.
2 Campbell B. Peveler R. DEC methods for appraising new
drugs. BMJ 1999;319:1005. (9 October.)
3 Nicholson T, Stein K. Low molecular weight heparins
(dalteparin and enoxaparin) compared with unfractionated
heparin for unstable angina and non-Q-wave myocardial
infarction. Southampton: Wessex Institute for Health
Research and Development; 1999. (Report No 93.)
4 Fox K. The role of antithrombins in improving outcome in
unstable angina. Br J Cardiol 1998;5(suppl 2):S7-9.
Reply by members of committee
Editor—Bosanquet and Fox’s criticisms of
the development and evaluation commit-
tee’s conclusions1 and report2 on low
molecular weight heparins are without
foundation.
The authors make much of the omission
from the report of the one year follow up
data from the ESSENCE trial.3 True,
electronic searching failed to identify Fox’s
paper, published with an uninformative title
and after we had searched the relevant data-
base. But we also had contact with
enoxaparin’s manufacturers and with
experts in the field, none of whom
mentioned the paper. It is unlikely that its
inclusion would have made a material
difference: the report already indicated that
enoxaparin was probably less costly and
more effective than unfractionated heparin,
even if its benefits lasted for only 30 days and
not one year. Furthermore, it is incorrect to
say that no abstracts of Fox’s paper were
included: one was (reference 24), but
because of past criticism this committee has
decided to use data from abstracts only in
sensitivity analyses. We make no apology for
this caution.
The committee’s discussion of the report
in March 1999 was animated. The final “not
proved” conclusion took account of the
whole range of evidence presented in the
report and was not formulaically derived
from the committee’s decision grid.4 The
committee recognised that important new
evidence was expected soon and so ear-
marked the report for early review.
Bosanquet and Fox have oversimplified
the correspondence since June 1999. Once
the ESSENCE follow up data3 were identi-
fied and their implications agreed, an
addendum was prepared (published on the
committee’s website (www.hta.nhsweb.nhs.
uk/rapidhta/) and circulated with new
copies of the report) and a full update was
scheduled. After discussion with the NHS
Executive it has now been decided to
withdraw the original report. The com-
mittee will consider the update in the next
few months, as originally planned. We reject
the assertion that this dialogue has not been
handled appropriately.
With regard to the final suggestion
about peer review, all of the committee’s
reports are shown to several (named)
experts in the field for their guidance and
comments before being finalised and pre-
sented to the committee.
Bosanquet and Fox comment on the
value of development and evaluation com-
mittee reports in providing decision makers
in the health service with rapid but systematic
reviews on the effectiveness and cost effective-
ness of treatments. The handling of this
report and of its criticisms show not the
weaknesses but the strengths of the system.
Bruce Campbell chairman of development and
evaluation committee (South East and South West regions)
Vascular Surgery Department, Royal Devon and
Exeter Healthcare NHS Trust, Royal Devon and
Exeter Hospital (Wonford), Exeter EX2 5DW
Ken Stein consultant in public health medicine
North and East Devon Health Authority,
Barnstaple EX31 1RW
Ruairidh Milne visiting senior lecturer in public
health medicine
Wessex Institute for Health Research and
Development University of Southampton,
Southampton SO16 7PX
R.Milne@soton.ac.uk
1 Campbell B, Peveler R. DEC methods for appraising new
drugs. BMJ 1999;319:1005. (9 October.)
2 Nicholson T, Stein K. Low molecular weight heparins
(dalteparin and enoxaparin) compared with unfractionated
heparin for unstable angina and non-Q-wave myocardial
infarction. Southampton: Wessex Institute for Health
Research and Development, 1999. (Report No 93.)
3 Fox K. The role of antithrombins in improving outcome in
unstable angina. Br J Cardiol 1998;5(suppl 2):S7-9.
4 Best L, Stevens A, Colin-Jones D. Rapid and responsive
health technology assessment: the development and
evaluation process in the South and West region of
England. J Clin Effect 1997;2:51-6.
Osteoporosis and coeliac
disease
Screening all patients with osteoporosis
would be inappropriate
Editor—In his review of coeliac disease
Feighery comments on the high incidence of
osteoporosis in coeliac patients and says that
this may be a presenting feature.1 He goes
further to recommend, however, that all
patients with osteoporosis should be
screened for coeliac disease by measurement
of endomysial antibodies.1 Most patients with
osteoporosis do not have coeliac disease, and
it is our experience that it is unusual for such
patients to present without some other
feature of coeliac disease. In their survey of 92
patients with osteoporosis Lindh et al
comment that none of those patients found
to have coeliac disease had intestinal symp-
toms, but no mention was made of anaemia.2
Such a proposal would have considerable
implications for resources, both in the cost of
the assays and in the substantial number of
patients that would require referral to the
gastroenterologists for intestinal biopsy. We
suggest that screening for coeliac disease be
reserved for when unexplained osteoporosis
presents in association with anaemia or low
serum concentrations of calcium in perma-
nently tired premenopausal women and men
aged 60 years who have a family history of
coeliac disease or any gastrointestinal
symptoms.
W E Fickling research registrar
Royal United Hospital, Bath BA1 3NG
Will.Fickling@btinternet.com
A K Bhalla consultant rheumatologist
Royal National Hospital for Rheumatic Diseases,
Bath BA1 1RL
1 Feighery C. Fortnightly review: coeliac disease. BMJ
1999;319:236-9. (24 July.)
2 Lindh E, Ljunghall S, Larsson K, Lavo B. Screening for
antibodies against gliadin in patients with osteoporosis.
J Intern Med 1992;231:403-6.
Author’s reply
Editor—I agree with Fickling and Bhalla
that it would be inappropriate to screen all
patients with osteoporosis for coeliac dis-
ease. The statement in the review that “all
patients” should be screened is overenthusi-
astic and should be amended to read “all
patients with unexplained osteoporosis.”
Because of the high prevalence of coeliac
disease, in particular clinically silent disease,
I believe that patients with unexplained
osteoporosis should be screened for coeliac
disease even when there are no additional
clinical clues pointing towards coeliac
disease. We screened 371 female patients
with suspected, but unexplained, osteoporo-
sis and confirmed coeliac disease in five
patients; two further patients were persist-
ently positive for endomysial antibody but
refused small intestinal biopsy. The findings
have been submitted for publication.
Conleth Feighery professor of immunology
Department of Immunology, St James’s Hospital
and Trinity College Dublin, Dublin 8, Republic of
Ireland
Hospital of the future
Health economics may be misleading
Editor—Posnett in his article asserts that “a
close observer of the NHS . . . might be
forgiven for thinking that the debate about
the concentration of acute hospital services
has been driven more by the needs of NHS
managers and the medical professions than
by the needs of the local populations that
they are supposed to serve.”1 As director of
the York Health Economics Consortium, he
explains that the apparent logic of rationali-
sation and mergers is not supported by the
evidence. He argues that service planners
would do well to give more prominence to
the importance of ensuring that hospital
services are local and easily accessible.
Fine words, but what about the rationali-
sation in Liverpool that followed the
consortium’s recommendations in 1992? In
their review of accident and emergency and
related acute services for Liverpool Health
Authority, the economists confidently pre-
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dicted that efficiencies in health care would
reduce the number of beds needed by 500.
Moreover, by combining these efficien-
cies with predictions of diminishing health
needs in a dwindling population, they
concluded that, by 2001, Liverpool and its
neighbouring districts would require up to
1000 fewer beds.2
Their case was supported by speculation
that comprehensive care in the future would
be more often delivered by general practi-
tioners and—despite fierce opposition by
local people and their doctors—it was
accepted. The consequences have been dire.
For want of beds anywhere in Liverpool,
patients in the new “super” emergency
department now routinely wait for 24 hours
or more in conditions that make everyone
miserable and angry. Even heroic efforts by
the staff have not prevented care for many
being seriously compromised.
The crisis here—as in so many other
parts of the NHS—results primarily from
undue reliance on untested health eco-
nomic theories and prompts a number of
questions. If transparent, evidence based
practice and accountability are required of
clinicians, should they not apply to health
economists? The answer would matter little
if this government—like its predecessors—
did not so clearly depend on health
economists to justify its policies. Indeed,
much of the hostility towards doctors
originates with the privileged health econo-
mists of York.3 Doctors’ requests for a
cautious approach to NHS reforms are
treated with scorn,4 but when will health
economists render themselves accountable
for the effects of their prescriptions?
L C Luke consultant in accident and emergency medicine
Royal Liverpool University Hospitals, Liverpool
L7 8XP
cluke@rluh-tr.nwest.nhs.uk
1 Posnett J. Is bigger better? Concentration in the provision
of secondary care. BMJ 1999; 319:1063-5. (16 October.)
2 Akehurst R, Robertson E, Slack R. A review of accident and
emergency and related acute services in Liverpool: Final report.
York: York Health Economists Consortium, University of
York, 1992.
3 Bloor K, Maynard A. Rewarding healthcare teams. BMJ
1998;316:569.
4 Brown C. Disgruntled doctors strike back at Blair’s broad-
side. Independent, 1999 Oct 6.
Maybe hospitals are not needed at all
Editor—With reference to Posnett’s article
on concentration in the provision of hospital
care,1 outside operating theatres and inten-
sive care units, the case for having hospitals
rests on two assumptions: firstly, that there are
advantages (either in terms of reduced costs
or improved outcomes) to providing 24 hour
care in a setting that encourages bed rest; and,
secondly, that there are advantages (either in
terms of reduced costs or improved out-
comes) to having easy access to a range of
other specialist staff. Our best estimate of the
case for bed rest is that it is at best ineffective
and at worst makes the outcome worse.2 We
all know how disorientating and incapacitat-
ing admission to hospital is for elderly people
(and most patients are elderly). We also all
know that social networks break down if
admission is prolonged.
What is the case for economies of scope?
There may be advantages in having a range
of specialist services, but do these outweigh
the disadvantages of cross infection and
overinvestigation?
Emergency abdominal surgery is carried
out in the same theatres as elective
procedures. In other settings where sterility
is important (such as the food industry), it
would be unthinkable to allow faeces to be
processed in the same building.
We are also all familiar with the way in
which patients have unrelated and often qui-
escent problems “worked up” by specialists
while they are in hospital. In the community,
the general practitioner would deal with these
problems, avoiding a great deal of unneces-
sary referral. Surely, with advances in technol-
ogy making changes possible, it is time for us
to rethink the settings in which care is
provided? Or are we simply wedded to hospi-
tals because they are the familiar institutions
in which we were trained?
Tom Marshall lecturer in public health medicine
University of Birmingham, Birmingham B15 2TT
marshatp@hsrc1.bham.ac.uk
1 Posnett J. Is bigger better? Concentration in the provision
of secondary care. BMJ 1999; 319:1063-5. (16 October.)
2 Allen C, Glasziou P, Del Mar C. Bed rest: a potentially
harmful treatment needing more careful evaluation. Lancet
1999;354:1129-33.
Seasonality of birth in children
with diabetes
Results of various studies differ
Editor—Rothwell et al have found evidence
for seasonality of birth in children with
diabetes from Great Britain but not else-
where.1 They do not, however, give ascer-
tainment estimates for the centres partici-
pating in the study. Consequently, selection
bias may play a part in their results, particu-
larly in those centres with low case
ascertainments.
Although this is a large multicentre study,
the authors have not analysed the pooled
data. They point out that sample sizes from
many centres were too small to provide
enough power for the seasonality of birth in
these children to be assessed. It would be
interesting to know if the analysis of the
pooled data still showed a significant pattern.
The authors have previously shown
evidence of seasonality of birth in children
with diabetes in Scotland, Yorkshire, and
England and Wales.2 In contrast, the current
report shows no evidence for this effect in
children born in England and Wales,
although the ÷2 value is greater than the one
quoted in their previous paper. It is difficult
to reconcile these two sets of data.
Rothwell et al also state that a similar pat-
tern has been found in the Netherlands.3 The
authors who reported the study there found
that more boys with diabetes were born in
April, May, and November but did not find an
effect either for girls or for boys and girls
combined.3 In contrast, Rothwell et al report a
significant seasonal pattern of birth, with a
peak in early summer and a trough in
winter.1 2 The pattern in Britain is clearly
different from that in the Netherlands.
We have examined this phenomenon by
the same methodology in our local register,
the Cornwall and Plymouth children’s
diabetes register.4 Children diagnosed with
type 1 diabetes under the age of 16 were
enrolled in our register, with 94.4% ascer-
tainment. The analysis was of 417 children
with diabetes born between 1970 and 1995.
Our results showed that no significant
seasonality of birth exists in the south west
of England (÷2 = 4.05, df = 2, P = 0.13). This
result is in line with results from Sardinia5
and some other European countries1 but is
contrary to the results presented by Roth-
well et al. In our opinion, the evidence
derived from such registers and its support
for the environmental cause of childhood
diabetes need to be assessed further.
Hongxin Zhao research student
H.Zhao-l@plymouth.ac.uk
Andrew G Demaine senior lecturer
B Ann Millward consultant diabetologist
Molecular Medicine Research Group, Plymouth
Postgraduate Medical School, University of
Plymouth, Plymouth PL6 8BX
1 Rothwell PM, Gutnikov SA, McKinney PA, Schober E,
Ionescu-Tirgoviste C, Neu A for the European Diabetes
Study Group. Seasonality of birth in children with diabetes
in Europe: multicentre cohort study. BMJ 1999;319:887-8.
(2 October.)
2 Rothwell PM, Staines A, Smail P, Wadsworth E, McKinney
P. Seasonality of birth of patients with childhood diabetes
in Britain. BMJ 1996;312:1456-7.
3 Jongbloet PH, Groenewoud HMM, Hirasing RA, Buuren
SV. Seasonality of birth in patients with childhood diabetes
in the Netherlands. Diabetes Care 1998;21:190-1.
4 Zhao HX, Stenhouse E, Soper C, Hughest P, Sanderson E,
Baumer JH, et al. Incidence of childhood onset type 1
diabetes mellitus in Devon and Cornwall, England,
1975-1996. Diabetes Med (in press).
5 Mutoni S, Wäänänen S, McKinney PA, Law GR, Bodansky
HJ, Mutoni S. The seasonal distribution of birth of patients
with insulin-dependent diabetes mellitus in Sardinia.
Diabetologia 1999;42(suppl 1):A86.
Maternally transmitted infection might
increase risk of diabetes
Editor—Rothwell et al write that further
studies are required to determine whether
abnormal seasonality of birth exists in child-
hood diabetes.1 Studies have been done in
Israel,2 China,3 and Japan4 of which the
authors seem not to be aware. These studies
support the hypothesis that in populations
with a higher incidence of type 1 diabetes a
maternally transmitted infection to the fetus
or newborn infant increases the risk of their
developing diabetes.
Zvi Laron director
WHO Collaborating Centre for the Study of
Diabetes in Youth, Endocrinology and Diabetes
Research Unit, Schneider Children’s Medical
Centre of Israel, Petah Tikva 49202, Israel
laronz@clalit.org.il
1 Rothwell PM, Gutnikov SA, McKinney PA, Schober E,
Ionescu-Tirgoviste C, Neu A for the European Diabetes
Study Group. Seasonality of birth in children with diabetes
in Europe: multicentre cohort study. BMJ 1999;319:887-8.
(2 October.)
2 Laron Z, Shamis I, Nitzan-Kaluski D, Ashkenazi I. Month of
birth and subsequent development of type 1 diabetes
(IDDM). J Pediatr Endocrinol Metab 1999;12:397-402.
3 Ye Chen R-G, Ashkenazi I, Laron Z. Lack of seasonality in
childhood IDDM (0.7-15 years) in Shanghai, China. J Pedi-
atr Endocrinol Metab 1998;11:461-4.
4 Kida K, Mimura G, Ito T, Murakami K, Ashkenazi I, Laron
Z, et al. Incidence of type I diabetes (IDDM) in children
(0-14 years) in Japan (1986-1990) including an analysis for
seasonality of onset and month of birth. Diabetic Med (in
press).
Letters
716 BMJ VOLUME 320 11 MARCH 2000 www.bmj.com
Rationing certainly exists in
treatment for cancer
Editor—I sympathise with the views given
in the news item by Woodman about the
report by the Campaign for Effective and
Rational Treatment1 and the letter by de
Takats2: funding for both supportive treat-
ment in cancer and cancer chemotherapy is
inadequate in the NHS. In my own field of
haematological oncology, decisions are
made daily that deny either the most
effective agents or those with fewest side
effects solely on grounds of cost. It is no
longer true (if it ever was) that the patient in
front of me will receive the best care that I
am capable of delivering; rather, he or she
will receive the highest quality of care that is
possible given what is affordable within the
directorate.
Bisphosphonates to prevent bone dis-
ease in myeloma are a case in point. Two
studies have shown their clinical efficacy.3 4
Their widespread use in my unit will cost an
additional £75 000 a year. This has been
identified as a substantial cost to our princi-
pal purchasers, who, while agreeing to their
use, cannot provide additional funding. This
results in the absurd situation where we ask
sympathetic general practitioner colleagues
to prescribe bisphosphonates, although the
NHS financial burden would probably be
less if they were prescribed by the hospital.
There are numerous other areas where
we as doctors ration access to optimum
treatment on grounds of affordability and
conspire not to tell patients. In my own field
the other drugs most frequently withheld
are serotonin antagonists (for emesis),
haematopoietic growth factors, purine ana-
logues, rituximab, and liposomal amphoter-
icin. I do not agree with Glynne-Jones that it
is not “primarily a question of money”1; in
my directorate it most certainly is. Despite
constant vigilance our pharmacy budget has
a projected overspend of £60 000 (annual
budget £670 000) and there is considerable
pressure within the trust to contain expendi-
ture.
Those of us working in oncology have
recognised for years that rationing exists in
the NHS. I hope that some of these conten-
tious areas may be resolved by definitive
guidance from the National Institute for
Clinical Excellence, although I doubt that
such guidance will result in the release of
additional funds. In the meantime should we
not be more honest with our patients?
Donald W Milligan consultant haematologist
Department of Haematology, Birmingham
Heartlands Hospital, Birmingham B9 5ST
milligd@heartsol.wmids.nhs.uk
1 Woodman R. NHS cancer patients denied supportive
treatments. BMJ 1999;319:1520. (11 December.)
2 de Takats PG. Cancer chemotherapy costs money. BMJ
1999;319:1572. (11 December.)
3 Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA,
Bordoni R, George S, et al. Efficacy of pamidronate in
reducing skeletal events in patients with advanced multiple
myeloma. N Engl J Med 1996;334:488-93.
4 McCloskey EV, MacLennan IC, Drayson MT, Chapman C,
Dunn J, Kanis JA. A randomized trial of the effect of
clodronate on skeletal morbidity in multiple myeloma.
MRC Working Party on Leukaemia in Adults. Br J Haema-
tol 1998;100:317-25.
Distress symptoms may be easy
to miss
Editor—MacCorquodale’s young woman
with a wart on her nose was trying to trans-
mit a distress signal on an unusual
wavelength.1 Whenever I hear of a suicide,
especially an unexpected one, I wonder
whether one of us in our profession failed to
receive, or recognise, such a signal.
The suicide I have had on my conscience
for 45 years was of a young man, an
immigrant to Australia from central Europe.
I had taken out his acutely inflamed appen-
dix a few months before and had got to
know him a little during his convalescence,
so my failure to recognise his problem was
all the more inexcusable.
He wanted to see me on a day when I was
frantically busy. Everything seemed to be
happening at once—two women in labour; an
accident at a nearby factory, with several men
needing stitches; and a waiting room full of
patients. His complaint was that he couldn’t
get a date with a girl he was attracted to and
thought he must smell. I saw him in the hall,
not my office, and was brusque, telling him
not to bother me with such a trivial problem
when he could see how busy I was. He turned
and walked quietly away.
Next morning I was called by the police,
wanting to know what he had seen me
about. He had a receipt from the reception-
ist for an office visit on the previous
afternoon, and that night he had put the
barrel of a rifle in his mouth and pulled the
trigger. I knew instantly what a terrible
wrong I had done him, but no amount of
lamentation could restore him to life.
I hope I never again failed to recognise
distress signals transmitted on unusual
wavelengths. In my teaching of medical stu-
dents I have often told this story of his need-
lessly wasted life—not to atone for my
missed diagnosis but in the hope that others
may learn from my terrible mistake.
John Last emeritus professor of epidemiology
University of Ottawa, Ottawa, ON K1H 8M5, Canada
jmlast@uottawa.ca
1 MacCorquodale DW. A memorable patient: The young
woman with a wart on her nose. BMJ 1999;319:1349. (20
November.)
Centralisation of cancer
services in rural areas has
disadvantages
Editor—Smith describes “disproportionate
time and energy” being spent in “a battle over
surgical services” in Dumfries and Galloway.1
In our rural practice of 2700 patients 32
cases of cancer were identified over 2.5 years.
When travel to local services was excluded
the 32 patients travelled on average 1479
km—over 20 hours by private car. Eleven died
of their disease over that period and travelled
an average of 1880 km, taking nearly 30
hours. No one chose ambulance transport,
but six had to rely on it as their sole method
of transport and three used a mixture of
ambulance transport and private car. One 84
year old patient who was receiving radio-
therapy described a 7.5 hour one way journey
by the patient transport service from Edin-
burgh to Stranraer. Even by car this would
have taken over three hours.
Patients who died survived an average
165 days, of which 22 days (13% of their
remaining life) was spent travelling to or in
remote (by rural perspective) hospitals.
One third of Scotland is regarded as
rural. Proposed centralisation of cancer serv-
ices2 places an extra burden on patients
already frail from cancer or the effects of
treatment. Will they benefit? Extrapolating
our figures to the Wigtownshire district
suggests that 482 800 km of patient travel
occurs a year and 5800 inpatient days are
spent in a cancer hospital more than three
hours’ travel from home. Four people from
Stranraer have been killed in traffic accidents
while visiting relatives in the past 15 years.
Solutions include developing and
improving use of community resources; bet-
ter personal communication and coopera-
tion between specialists and general practi-
tioners; block clinic bookings, allowing
transport to be shared; and mobile facilities
for imaging, investigations, or treatment.
Patients travelled to Edinburgh rather than
Glasgow for treatment (an extra 113 km) for
reasons that did not seem to be patient cen-
tred. Telemedicine seems to have made little
impact on travelling.3
Rural patients suffer the financial penalty
of having to travel large distances. This is
compounded by social and emotional depri-
vation caused by separation from home and
friends. They have to balance spending 13%
of their remaining life in a distant and lonely
hospital against benefit from unpleasant and
painful treatment. Visitors find the travel
expensive and inconvenient.
Where cancer services are provided
locally the uptake of treatment increases.4 If
equity of access is important5 then where
such barriers to treatment exist and services
are made less, not more accessible, we have
to strain to be optimistic.
A Gordon Baird general practitioner
AGordonBaird@aol.com
C Mary Donnelly general practitioner
Nigel T Miscampell general practitioner
Helen D Wemyss practice nurse
The White House, Sandhead, Wigtownshire
DG9 9JA
1 Smith R. The NHS in Dumfries and Galloway: straining
but optimistic. BMJ 1999;319:1123-7. (23 October.)
2 Scottish Cancer Co-ordinating and Advisory Committee.
Commissioning cancer services in Scotland: report to the chief
medical officer. Scottish Office Department of Health. Edin-
burgh: Stationery Office, 1996.
3 Kunkler IH, Rafferty P, Hill DM, Henry M, Foreman D.
Telemedicine. BMJ 1997;314:521.
4 Campbell NC, Ritchie LD, Cassidy J, Little J. Systematic
review of cancer treatment programmes in remote and
rural areas. Br J Cancer 1999;80:1275-80.
5 Scottish Executive Health Department. Fair shares for all:
report of the national review of resource allocation for the NHS
in Scotland. Edinburgh: Scottish Executive, 1999.
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